HUMACYTE INC. - COMMO

Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference

01 Mar 2024 09:16:19 By Nasdaq GlobeNewswire

Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock

29 Feb 2024 21:18:05 By Nasdaq GlobeNewswire

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

29 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma

09 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel™ (HAV™) for the Treatment of Vascular Trauma

12 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference

24 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma

17 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Humacyte Third Quarter 2023 Financial Results and Business Update

09 Nov 2023 16:01:00 By Nasdaq GlobeNewswire

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 9, 2023

02 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model

16 Oct 2023 08:55:42 By Nasdaq GlobeNewswire

Humacyte to Present at the Cantor Global Healthcare Conference

21 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Humacyte to Host In-Person KOL Event at the New York EDITION on September 20, 2023

18 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma

12 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Humacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma Evaluating its Human Acellular Vessel™ (HAV™) Tuesday, September 12, 2023 at 8:00 AM ET

11 Sep 2023 17:00:00 By Nasdaq GlobeNewswire

Results From Mayo Clinic Clinical Study of Humacyte’s Human Acellular Vessel™ (HAV™) in Treatment of Patients with Chronic Limb Ischemia Presented at Midwestern Vascular Conference

11 Sep 2023 08:00:01 By Nasdaq GlobeNewswire

Humacyte Presents Clinical Performance of Human Acellular Vessel™ (HAV™) From Ukrainian Humanitarian Program

15 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Humacyte Second Quarter 2023 Financial Results and Business Update

14 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 14, 2023

07 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Humacyte Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel™ (HAV™)

03 Aug 2023 08:00:01 By Nasdaq GlobeNewswire

Humacyte Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) for Vascular Trauma Repair

26 Jul 2023 08:00:01 By Nasdaq GlobeNewswire